3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
482
pembrolizumab
456
Magnetic Resonance Spectroscopy
419
Carboplatin
322
Cyclophosphamide
317
Biopsy
270
Cisplatin
263
Radiotherapy
238
Paclitaxel
227
Gemcitabine
222
Bevacizumab
214
Nivolumab
190
fludarabine
185
venetoclax
172
Drug Therapy
165
Blood Specimen Collection
157
Dexamethasone
156
Oxaliplatin
154
Injections
152
Capecitabine
152
Fluorouracil
144
Docetaxel
142
Standard of Care
138
Radiosurgery
136
Rituximab
125
Pemetrexed
115
durvalumab
113
atezolizumab
110
Leucovorin
110
Surveys and Questionnaires
104
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Serotonin 5-HT3 Receptor Antagonists
×
1 year
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled